← Russell 3000 cross-section

LLY ELI LILLY & Co

Trailing twelve months to 2026-06-30 · as filed 2026-08-05, not restated
Healthcare

Scale

Market cap
$1,057.6bn
Revenue TTM
$79.7bn
Net income TTM
$26.7bn
Free cash flow
Composite score
Sector rank
#11

Valuation

P / E
39.6
EV / EBITDA
EV / sales
13.9
FCF yield
Earnings yield vs 10-yr
-2.20pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
33.5%
EBITDA margin
ROE
78.8%
ROIC
Revenue growth
49.6%

Insider activity, last 90 days

Net open-market
$-18.84m
Buyers
0
Sellers
4

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Financial Results The following table summarizes certain financial information: Revenue increased for the three and six months ended June 30, 2026, driven primarily by increased volume, partially offset by lower realized prices. The increased volume and the lower realized prices during the three and six months ended June 30, 2026 were primarily driven by Mounjaro and Zepbound. Net income and earnings per share for the three months ended June 30, 2026 increased primarily due to higher gross margin, partially offset by higher acquired IPR&D charges, asset impairment, restructuring, and other special charges, and marketing, selling, and administrative expenses. …ELI LILLY & Co, 10-Q, period ended 2026-06-30, filed 2026-08-05

Read the full passage →